GSPT1

Across TCGA pan-cancer cohorts, GSPT1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of GSPT1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where GSPT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GSPT1 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

LIHC, COAD, and STAD are the cancer types where GSPT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GSPT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	III,IV	+0.911	<.001	9	view →
COAD	All	II,III,IV	+0.550	<.001	9	view →
STAD	All	II,III,IV	+0.695	<.001	8	view →
THCA	Female	All	−0.381	<.001	8	view →
HNSC	Male	All	+0.526	<.001	7	view →
BRCA	All	II,III,IV	+0.609	<.001	6	view →
KIRC	Male	III,IV	−0.517	<.001	6	view →
CHOL	All	All	+1.492	<.001	5	view →
KIRP	All	II,III,IV	+0.500	.001	5	view →
READ	All	III,IV	+0.839	.011	2	view →
PRAD	All	All	+0.401	<.001	2	view →
ESCA	All	All	+0.496	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

GSPT1–LIHC

Open the LIHC breakdown →